

Algorithm ([www.hivdb.stanford.edu](http://www.hivdb.stanford.edu); HIVdb version 6.1.1F; 2012 webService version beta-1.0.1) to identify mutations and to determine drug susceptibility. Sequences were analysed by using different lists of mutations (Bennett D. 2009; Johnson V. 2011). Trends in the prevalence of drug resistance mutations were calculated by logistic regression.

**Results** A total of 9,528 patients from five study centres were included into analysis. 4,989 viral sequences were collected from 34% (3,267/9,528) of these patients. 47% (2,365/4,989) of sequences were produced from patients being treatment naïve and 50% (2,495/4,989) from patients under treatment. TDR was identified in 10% (203/1,950) of viral strains. The prevalence of TDR over time was stable at 10.4% (95% CI 9.1–11.8; OR: 0.98; 95% CI 0.92–1.04;  $p_{\text{for trend}} = 0.6$ ; 2001–2011). NRTI-resistance was determined in 7% (128/1,950), followed by 3% NNRTI- and PI-resistance, respectively (NNRTI: 61/1,950; PI: 56/1,950). Prevalence of ADR in treated patients was high (61%; 1,500/2,453 of sequences) but declined significantly over time (OR: 0.8; 95% CI 0.77–0.83;  $p_{\text{for trend}} < 0.001$ ; 2001–2011). Within drug classes NNRTI-resistance was predominant (56%; 834/1503), followed by NRTI-resistance in 52% (1,139/2,194) of sequences of patients with ADR exposed to these drug classes. PI-resistance was identified in 30% (543/1773). Integrase-resistance was determined in 8% (13/161) of integrase-sequences.

**Discussion** Prevalence of TDR is highly stable in this unselected study population, whereas ADR declined significantly over the time, indicating that this decline was presumably influenced by ART related effects, broader resistance testing and resistance test guided therapy.

### 019.3 ESTIMATE OF THE PREVALENCE OF TRANSMITTED DRUG RESISTANCE (TDR) AND ACQUIRED DRUG RESISTANCE (ADR) IN A HIV RESISTANCE STUDY OF THE GERMAN CLINSURV-HIV COHORT

doi:10.1136/sextrans-2013-051184.0193

<sup>1</sup>B Bartmeyer, <sup>1</sup>D Schmidt, <sup>1</sup>C Kollan, <sup>2</sup>G Fätkenheuer, <sup>3</sup>H Stellbrink, <sup>4</sup>J Bogner, <sup>5</sup>B O Jensen, <sup>6</sup>M Stoll, <sup>1</sup>C Kücherer, <sup>1</sup>O Hamouda. <sup>1</sup>Robert Koch Institute, Berlin, Germany; <sup>2</sup>Clinic for Internal Medicine, University of Cologne, Germany; <sup>3</sup>ICH Study Centre Hamburg, Hamburg, Germany; <sup>4</sup>Dept. of Infectious Diseases, Medical Clinic, Ludwig Maximilians University Munich, Germany; <sup>5</sup>Clinic of Gastroenterology and Hepatology, Heinrich Heine University Düsseldorf, Germany; <sup>6</sup>Clinic for Immunology and Rheumatology, Medical University Hanover, Germany

**Aim** To estimate the prevalence of HIV-TDR and ADR in one resistance study of the German ClinSurv-HIV cohort.

**Method** The ClinSurv study is a national open multi-centre long term observational cohort with 15 participating clinical centres (n = 16,750 patients; 31.12.2011). In a resistance study all ClinSurv patients in five centres were identified. Sequences were processed through the Stanford University Genotypic Resistance Interpretation

**STI**

## **O19.3 Estimate of the Prevalence of Transmitted Drug Resistance (TDR) and Acquired Drug Resistance (ADR) in a HIV Resistance Study of the German ClinSurv-HIV Cohort**

B Bartmeyer, D Schmidt, C Kollan, G Fätkenheuer, H Stellbrink, J Bogner, B O Jensen, M Stoll, C Kücherer and O Hamouda

*Sex Transm Infect* 2013 89: A63  
doi: 10.1136/sextrans-2013-051184.0193

---

Updated information and services can be found at:  
[http://sti.bmj.com/content/89/Suppl\\_1/A63.2](http://sti.bmj.com/content/89/Suppl_1/A63.2)

---

*These include:*

### **Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

---

### **Topic Collections**

Articles on similar topics can be found in the following collections

[Drugs: infectious diseases](#) (3182)  
[HIV / AIDS](#) (2514)  
[HIV infections](#) (2514)  
[HIV/AIDS](#) (2514)

---

### **Notes**

---

To request permissions go to:  
<http://group.bmj.com/group/rights-licensing/permissions>

To order reprints go to:  
<http://journals.bmj.com/cgi/reprintform>

To subscribe to BMJ go to:  
<http://group.bmj.com/subscribe/>